Stereotaxis

Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System

ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval marks the official commercial launch of the world’s first integrated "digital cockpit" for robotic electrophysiology

Stereotaxis

Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"

ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Synchrony™ system. The clearance marks the final